LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 513 | 7328 | 10362 | 0.7074 | 0.8463 |
MCF 10A | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 513 | 3966 | 10362 | 0.3832 | 0.6011 |
MCF 10A | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 513 | 2212 | 10362 | 0.2135 | 0.4000 |
MCF 10A | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 513 | 1073 | 10362 | 0.1036 | 0.1761 |
MCF 10A | Dovitinib | 10 | uM | LJP5 | 72 | hr | 513 | 652 | 10362 | 0.0627 | 0.0414 |
MCF 10A | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 513 | 9415 | 10362 | 0.9088 | 0.9561 |
MCF 10A | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 513 | 9574 | 10362 | 0.9242 | 0.9635 |
MCF 10A | GSK 690693 | 0.37 | uM | LJP5 | 72 | hr | 513 | 9016 | 10362 | 0.8702 | 0.9363 |
MCF 10A | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 513 | 7238 | 10362 | 0.6984 | 0.8408 |
MCF 10A | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 513 | 7222 | 10362 | 0.6966 | 0.8394 |
MCF 10A | GSK 690693 | 10 | uM | LJP5 | 72 | hr | 513 | 7361 | 10362 | 0.7104 | 0.8482 |
MCF 10A | SNS-032 | 0.04 | uM | LJP6 | 72 | hr | 513 | 6891 | 10473 | 0.6577 | 0.8158 |
MCF 10A | SNS-032 | 0.12 | uM | LJP6 | 72 | hr | 513 | 662 | 10473 | 0.0632 | 0.0586 |
MCF 10A | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 513 | 549 | 10473 | 0.0524 | 0.0155 |
MCF 10A | SNS-032 | 1.11 | uM | LJP6 | 72 | hr | 513 | 486 | 10473 | 0.0464 | -0.0145 |
MCF 10A | SNS-032 | 3.33 | uM | LJP6 | 72 | hr | 513 | 488 | 10473 | 0.0466 | -0.0119 |
MCF 10A | SNS-032 | 10 | uM | LJP6 | 72 | hr | 513 | 407 | 10473 | 0.0389 | -0.0534 |
MCF 10A | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 513 | 351 | 10473 | 0.0335 | -0.0847 |
MCF 10A | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 513 | 427 | 10473 | 0.0408 | -0.0420 |
MCF 10A | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 513 | 487 | 10473 | 0.0465 | -0.0133 |
MCF 10A | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 513 | 588 | 10473 | 0.0562 | 0.0319 |
MCF 10A | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 513 | 525 | 10473 | 0.0502 | 0.0048 |
MCF 10A | Afatinib | 10 | uM | LJP6 | 72 | hr | 513 | 561 | 10473 | 0.0536 | 0.0195 |
MCF 10A | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 513 | 3073 | 10473 | 0.2931 | 0.5040 |
MCF 10A | GSK1904529A | 0.12 | uM | LJP6 | 72 | hr | 513 | 3050 | 10473 | 0.2910 | 0.5025 |